Description
Tradename:
Citalo 40 mg
Compound:
Each tablet contains:
Citalopram hydrobromide 49.92 mg, which corresponds to citalopram 40 mg.
Auxiliary components:
Lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, croscarmellose.
Properties:
Citalopram is an antidepressant belonging to the group of selective serotonin reuptake inhibitors (SSRIs). It has a pronounced ability to inhibit serotonin reuptake, has no or very weak ability to bind to a number of receptors, including gamma-aminobutyric acid (GABA), H1-histamine, D1- and D2-dopamine receptors; α1-, α2-, beta-adrenergic; benzodiazepine and m-cholinergic receptors, which leads to an almost complete absence of unwanted effects.
The antidepressant effect usually develops after 2-4 weeks of treatment.
Indications:
– moderate to severe depressive episodes;
-panic disorders.
Directions for use and dosage:
Sitalo is taken orally once a day (without chewing, with a small amount of liquid). The drug can be used at any time of the day, regardless of food intake; it is advisable to take the drug at the same time of day.
Depression:
Treatment for depression begins with taking 20 mg of Sitalo per day. Depending on the individual response of the patient and the severity of depression, the dose can be increased to a maximum of 40 mg per day.
Panic disorder:
For panic disorders, the recommended dose is 10 mg per day for 1 week, then the dose is increased to 20 mg per day. The daily dose, depending on the individual response of the patient, can subsequently be increased to 40 mg per day.
The effect appears after 2-4 weeks, the duration of treatment is determined by the patient’s condition, the effectiveness and tolerability of the therapy and averages 6 months.
Contraindications:
Hypersensitivity to Sitalo or to any of the excipients included in this drug;
Sitalo should not be used in combination with MAO inhibitors (MAOIs), including selegiline, moclobemide, linezolid (an antibiotic), or for 14 days after stopping their use. Treatment with MAO inhibitors can be started no earlier than 7 days after stopping citalopram;
Sitalo is contraindicated when used simultaneously with drugs that prolong the QT interval on the ECG (in particular, with pimozide), as well as with congenital prolongation of the QT interval;
– children under 18 years of age are a contraindication for the use of citalopram, since the effectiveness and safety of its use at this age have not been established.
Precautionary measures:
Sitalo should not be prescribed to pregnant and breastfeeding women unless the potential clinical benefit outweighs the theoretical risk, because The safety of the drug during pregnancy and lactation in women has not been established.
Due to the possibility of suicide attempts, patients with depression require careful monitoring of patients at the beginning of treatment and the appointment of minimal effective doses to reduce the risk of overdose.
Side effects:
From the central nervous system: drowsiness, headache, tremor, dizziness; migraine, paresthesia, sleep disorder;
From the mental sphere: agitation, nervousness; decreased libido, anxiety, confusion, drowsiness, impaired concentration, strange dreams, amnesia; From the digestive system: dry mouth, nausea, constipation; vomiting, flatulence, diarrhea, abdominal pain, hepatitis.
From the cardiovascular system: palpitations; tachycardia, arterial hypertension, orthostatic hypotension.
From the senses: disturbance of accommodation; taste disturbances, visual disturbances.
Rhinitis, sinusitis, painful urination, polyuria. Changes in appetite, weight loss. Increased sweating, skin rash, itching.
Storage method:
Store at a temperature not exceeding 30 degrees.
